课题基金 / 基金详情

Molecular mechanism of TRIM25 and ZAP mediated antiviral inhibition of arenavirus replication

Molecular mechanism of TRIM25 and ZAP mediated antiviral inhibition of arenavirus replication
TRIM25和ZAP介导的抗病毒抑制沙粒病毒复制的分子机制
批准号:
2885907
负责人:
金额:
$0.0万
依托单位:
依托单位国家:
英国
项目类别:
Studentship
财政年份:
2023
资助国家:
英国
项目状态:
未结题
起止时间:
2023 至 --

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
This joint project bridges across the virology and structural biology research programs in the Foster, Borkar and Dunham groups, focussing on the cellular antiviral mechanisms that that inhibit viral infection and the virus -host interactions that govern these. The Foster group focusses on the largest family of haemorrhagic fever causing viruses known as arenaviruses. These zoonotic viruses are rapidly expanding in their genetic diversity leading to increased annualoutbreaks in endemic regions and to sporadic imported outbreaks in globally, including recent cases in the UK (1). Understanding how host antiviral proteins block arenavirus replication is imperative to addressing current knowledge gaps on the viral lifecycle processes that are key for the development of effective vaccines and treatments (1).Recent proteomics studies in the Foster lab, identified the interaction between the arenavirus nucleoprotein, NP and the antiviral E3 ligase tripartite motif-containing protein 25 (TRIM25), a key component of the innate immune response that inhibits the replication of a diverse range of pathogenic viruses, but previously unknown for arenaviruses (2). NP is the most abundantly expressed arenavirus protein, is a major orchestrator of host immunosuppression during virusinfection and encapsidates the viral RNA, forming the viral ribonucleocomplexes (vRNPs) needed for infection initiation (1). Using arenavirus infection and CRISPR/Cas9 knockout studies, we have shown that TRIM25 significantly restricts arenavirus replication, that TRIM25 re-localises to NP-containing viral replication sites and that NP- overexpression is sufficient to induce this re-localisation.TRIM25 was recently identified as key cofactor of the zinc-antiviral protein, ZAP, that targets viral RNAs containing CpG dinucleotides leading to promotion of viral RNA degradation and/or inhibition of viral RNA translation (2). We have demonstrated that ZAP also potently inhibits arenavirus replication and as TRIM25 is also an RNA binding protein, and it remains to be determined how TRIM25 and ZAP activity is co-modulated by their RNA interactions. The molecular structure of TRIM25 is an anti-parallel dimer formed through its coiled-coil domain, that can further multimerise through dimerisation of its N-terminal RING domain, containing E3-ubiquitin ligase activity. The ZAP and other ligand-binding C-terminal PRYSPRY domain is located on either side of the coiled-coil (2).We hypothesise that TRIM25 may multimerise around the helical vRNP complexes, driving disassembly and exposing RNA sites for ZAP recruitment and subsequent RNA degradation.Thus, this project aims to use a combination of structural biology (expertise in the Borkar group), biochemistry and molecular virology techniques to:Characterise how TRIM25 interacts with arenavirus NP protein and with arenavirus viral RNAs with and without ZAP through mutagenesis and arenavirus replication experimentsRecombinantly express and purify TRIM25 and ZAP proteins alone, in complex and in the presence of arenaviral RNAVisualise by electron microscopy and/or X-ray crystallography apo-structures and TRIM25- NP and TRIM25-NP-RNA-ZAP complexes, incorporating specific mutations that modify RNA and cofactor binding.Given the molecular tractability of this antiviral mechanism across diverse RNA and DNA viruses, findings from this work will provide key evidence that could transform our understanding of innate immune mechanisms and influence therapeutic design.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
国内基金
海外基金
糖尿病ED中成纤维细胞衰老调控内皮细胞线粒体稳态失衡的机制研究
  • 批准号:
    82371634
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    赵福军
  • 依托单位:
PRNP调控巨噬细胞M2极化并减弱吞噬功能促进子宫内膜异位症进展的机制研究
  • 批准号:
    82371651
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    赵栋
  • 依托单位:
CBP/p300-HADH轴在基础胰岛素分泌调节中的作用和机制研究
  • 批准号:
    82370798
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    王晓
  • 依托单位:
生物钟核受体Rev-erbα在缺血性卒中神经元能量代谢中的改善作用及机制研究
  • 批准号:
    82371332
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    胡琴
  • 依托单位: